U.S. markets closed

CVS Health Corporation (CVS.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
49.07+0.88 (+1.84%)
At close: 8:04AM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close48.19
Open49.07
Bid0.00 x 20000
Ask0.00 x 20000
Day's Range49.07 - 49.07
52 Week Range47.91 - 69.24
Volume180
Avg. Volume223
Market Cap65.954B
Beta (5Y Monthly)0.65
PE Ratio (TTM)7.80
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.70 (3.52%)
Ex-Dividend DateJul 22, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Market Crash 2.0: 2 Stocks to Buy Right Now to Keep Your Portfolio Safe
      Motley Fool

      Market Crash 2.0: 2 Stocks to Buy Right Now to Keep Your Portfolio Safe

      You could add either of these giants to your portfolio, sit back, and watch the gains trickle in -- even in the worst of times.

    • Better Buy: Teladoc vs. CVS Health
      Motley Fool

      Better Buy: Teladoc vs. CVS Health

      These two healthcare stocks both have their advantages now, but one may be better poised for steady growth.

    • 3 Cheap Stocks You Can Buy and Hold for Decades
      Motley Fool

      3 Cheap Stocks You Can Buy and Hold for Decades

      The big pharma stock is available at a discount primarily because investors aren't sure how AbbVie will perform once its top-selling drug Humira begins to face biosimilar rivals in the U.S. beginning in 2023. Rinvoq won Food and Drug Administration (FDA) approval last year for treating rheumatoid arthritis, while Skyrizi scored FDA approval for treating plaque psoriasis. AbbVie is evaluating both drugs in late-stage studies targeting other autoimmune diseases, as well.